Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021-01455-x, 2021)

Autor: Dam, T, Golbe, LI, Hoglinger, GU, Grundman, M, Yang, LL, Tidemann-Miller, B, Kupferman, J, Harper, K, Kamisoglu, K, Wald, MJ, Graham, DL, Gedney, L, O'Gorman, J, Haeberlein, SB, Aiba, I, Antonini, A, Apetauerova, D, Azulay, JP, Martinez, EB, Bang, J, Barone, P, Barrett, M, Bega, D, Berg, D, Corrales, KB, Bordelon, Y, Boxer, AL, Brandt, M, Brueggemann, N, Castelnovo, G, Ceravolo, R, Chuang, RD, Chung, SJ, Church, A, Corvol, JC, Cudia, P, Dale, M, Defebvre, L, Drapier, S, Driver-Dunckley, ED, Ebersbach, G, Eggert, KM, Ellenbogen, A, Eusebio, A, Evans, AH, Fedorova, N, Finger, E, Foubert-Samier, A, Ghosh, B, Golbe, L, Perez, FG, Grossman, M, Hall, D, Hamada, K, Hasegawa, K, Hoeglinger, G, Honig, L, Houghton, D, Huang, XM, Isaacson, S, Koh, S, Bojarski, JK, Lang, ANE, Leigh, PN, Litvan, I, Lozano, JJL, Moreno, JLLS, Ludolph, AC, Piudo, MRL, Torres, IM, McFarland, N, Meissner, W, Mestre, T, Rivera, PM, Molho, E, Mollenhauer, B, Morris, HR, Murata, M, Obi, T, Magne, FO, O'Suilleabhain, P, Pahwa, R, Pantelyat, A, Pavese, N, Pokhabov, D, Prudlo, J, Rodriguez-Porcel, F, Rowe, J, Savitt, J, Schnitzler, A, Schulz, JB, Seppi, K, Shah, BI, Shill, H, Shprecher, D, Stamelou, M, Steiger, M, Takahashi, Y, Takigawa, H, Tartaglia, C, Toenges, L, Truong, D, Tse, W, Tuite, P, Volc, D, Wills, AMA, Woitalla, D, Xie, T, Yuasa, T, Zauber, SE, Zesiewicz, T

Publikováno v: NATURE MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::c4d2fa80ba30f6be89ae19d1c2727383
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13862

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study.

Autor: Kassubek J; Department of Neurology, University Hospital Ulm, Ulm, Germany.; German Centre for Neurodegenerative Diseases, Ulm, Germany., Stocchi F; University San Raffaele Roma and Institute for Research and Medical Care IRCCS San Raffaele Pisana, Rome, Italy., Martinez EB; Hospital Universitari General de Catalunya, Calle Pedro i Pons, 1, Barcelona, Spain., Pahwa R; University of Kansas Medical Center, Kansas City, KS, USA., Ondo W; Houston Methodist Neurological Institute, Scurlock Tower 6560 Fannin St, Houston, TX, USA.; Weill Cornell Medical School, New York, NY, USA., Zhang Y; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA., Bowling A; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA., Pappert E; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.; Neurology Associates, San Antonio, TX, USA., Isaacson S; Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA., Wu S; Sumitomo Pharma America, Inc., 84 Waterford Drive, Marlborough, MA 01752, USA.

Publikováno v: Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2023 Nov 09; Vol. 16, pp. 17562864231209240. Date of Electronic Publication: 2023 Nov 09 (Print Publication: 2023).